Defective immunogenic cell death of HMGB1-deficient tumors: compensatory therapy with TLR4 agonists.
about
Immunodynamics: a cancer immunotherapy trials network review of immune monitoring in immuno-oncology clinical trialsConcepts and mechanisms underlying chemotherapy induced immunogenic cell death: impact on clinical studies and considerations for combined therapiesPrognostic and Predictive Value of DAMPs and DAMP-Associated Processes in CancerBiomarkers of immunogenic stress in metastases from melanoma patients: Correlations with the immune infiltrateScreening of novel immunogenic cell death inducers within the NCI Mechanistic Diversity SetTrial Watch: Toll-like receptor agonists in oncological indications.Trial watch: Immunostimulatory cytokines in cancer therapy.Treatment of osteosarcoma with microwave thermal ablation to induce immunogenic cell deathDendritic-cell-based therapeutic cancer vaccinesHMGB1 in health and disease.Serum HMGB1 is a predictive and prognostic biomarker for oncolytic immunotherapy.Combinatorial strategies for the induction of immunogenic cell death.T-cell subsets in peripheral blood and tumors of patients treated with oncolytic adenoviruses.Transcriptional profiling provides insights into metronomic cyclophosphamide-activated, innate immune-dependent regression of brain tumor xenograftsTumor infiltrating CD8(+) T lymphocyte count is independent of tumor TLR9 status in treatment naïve triple negative breast cancer and renal cell carcinomaAnnexin A2 binds to endosomes and negatively regulates TLR4-triggered inflammatory responses via the TRAM-TRIF pathway.Molecular and Translational Classifications of DAMPs in Immunogenic Cell Death.Rituximab-induced HMGB1 release is associated with inhibition of STAT3 activity in human diffuse large B-cell lymphoma.Morphometric analysis of immunoselection against hyperploid cancer cellsAssessment of Radiation Induced Therapeutic Effect and Cytotoxicity in Cancer Patients Based on Transcriptomic Profiling.Combined evaluation of LC3B puncta and HMGB1 expression predicts residual risk of relapse after adjuvant chemotherapy in breast cancer.The presence of LC3B puncta and HMGB1 expression in malignant cells correlate with the immune infiltrate in breast cancer.Contribution of RIP3 and MLKL to immunogenic cell death signaling in cancer chemotherapy.Dendritic cells, inflammation, and breast cancer.Harnessing of Programmed Necrosis for Fighting against Cancers.Targeted near infrared hyperthermia combined with immune stimulation for optimized therapeutic efficacy in thyroid cancer treatment.Overexpression of apolipoprotein A-I fused to an anti-transforming growth factor beta peptide modulates the tumorigenicity and immunogenicity of mouse colon cancer cells.Cytotoxic effects of chemotherapy on cancer and immune cells: how can it be modulated to generate novel therapeutic strategies?Advancing Immunotherapy in Metastatic Breast Cancer.The immune contexture in cancer prognosis and treatment.The novel immunomodulator IMMUNEPOTENT CRP combined with chemotherapy agent increased the rate of immunogenic cell death and prevented melanoma growth.TLR4/IFNγ pathways induce tumor regression via NOS II-dependent NO and ROS production in murine breast cancer modelsConsensus guidelines for the detection of immunogenic cell death.A systematic investigation of the maximum tolerated dose of cytotoxic chemotherapy with and without supportive care in mice.Trial Watch: Anticancer radioimmunotherapy.Trial watch: Dendritic cell-based interventions for cancer therapy.Trial Watch: Toll-like receptor agonists for cancer therapy.An autophagy-dependent anticancer immune response determines the efficacy of melanoma chemotherapy.Identification of pharmacological agents that induce HMGB1 release.Post-translational modifications of high mobility group box 1 and cancer.
P2860
Q26765115-AED188AF-CB88-4B4D-9DEE-B3BBC921BE4CQ26781215-7D30D5D8-EAE3-4267-AE19-D35E77B2378CQ26795466-C85E7A31-960C-4CA4-B0F1-4978F239CDF2Q30276247-3E0376C7-D082-486E-9D18-7E97B1624959Q33776379-EA574435-5BED-40CA-A659-23A3F6D4FC98Q33878578-465AAF0C-F59D-40CE-A8F7-DC5B90938D23Q33880165-8B7F81DC-93EE-43F8-A49B-25AD3BC44FCDQ34227797-859E8D95-860A-410F-A66E-F373D28F9D51Q34360094-B0DE512F-BAD1-4E83-A44C-5D63099679DAQ34622835-7A05EF66-CB08-44B2-9439-73C493BABDCFQ35506253-9F5BCCF9-5524-4436-A0A1-CDF98F3FE670Q35535140-8CCA6278-3C78-406D-82D4-514BAB26EC35Q35594838-E67054F6-6804-4CB1-AA0E-BD67C2DF337BQ35624661-66F2F639-7532-4806-AC13-68E9F8365757Q35798941-9EE72471-7981-48A2-96B9-12C807D2C99CQ36242151-2DBB1845-83FB-4E53-8621-0A3A348329B9Q36301061-031117EF-4FF9-4349-833E-D1CADEDA7A07Q36413919-7FE71CCD-E8FB-4237-89C2-547E5D3EBA53Q36562331-D4342F18-C148-4755-8073-D574107C0693Q36667200-3ED5DD81-A508-4AA9-A4F0-6BE1AE1ABC41Q36777278-4CC4268A-9E77-4E82-B9AB-E01F8E1B12D7Q36862687-B3B731E2-B762-4CD8-824D-B320326533FEQ37078968-5CED9C98-FA8B-41D8-BEBE-AE81D889B2C5Q37456825-9A10D43D-7CAB-4E47-B772-7C34F62D9BA9Q38227878-F709617B-8232-4258-A2C5-22FAAF3A515DQ38803440-6ACC5E45-4DA7-4A89-BB30-621F164F9249Q38896948-838C7CFD-E943-46BA-BD70-8AFCBAC364E0Q38963228-6586AE96-4596-4016-A2A2-E0F1C7B42B0CQ39324161-4BEC2A9F-3EDC-4941-8ED2-817B040A6CB6Q39456999-F346DA29-2E9D-49E9-BCC3-F7511DA7E907Q40128947-DA6D8357-1F6F-4055-976A-1807B80FD98BQ42122613-D7F5BAEC-7BDD-4494-AEF1-7359FA9221EBQ42553556-4E0360DD-9F99-48CA-93B4-1D0A4F065FCAQ42690847-AB7E12EF-85DE-4A65-A094-E55A93DABC90Q42847992-3217B637-0293-413F-B3AB-4D3FFB998A3CQ42867339-48CD59D4-C7D5-4941-A8B1-0CB715A616A6Q42969291-A5ACE5E8-C2DE-4B2A-BE56-5C67E643E1E0Q43104031-3E2EFA03-75BA-4ED9-B9FF-5458FDF5D25CQ46251847-C5983C8D-D731-4A41-9F2A-45FE2E0A562EQ47220872-31AEF389-DDC2-48EE-9AE3-C73E8ED7154E
P2860
Defective immunogenic cell death of HMGB1-deficient tumors: compensatory therapy with TLR4 agonists.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 28 June 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Defective immunogenic cell dea ...... ry therapy with TLR4 agonists.
@en
Defective immunogenic cell dea ...... ry therapy with TLR4 agonists.
@nl
type
label
Defective immunogenic cell dea ...... ry therapy with TLR4 agonists.
@en
Defective immunogenic cell dea ...... ry therapy with TLR4 agonists.
@nl
prefLabel
Defective immunogenic cell dea ...... ry therapy with TLR4 agonists.
@en
Defective immunogenic cell dea ...... ry therapy with TLR4 agonists.
@nl
P2093
P2860
P50
P356
P1476
Defective immunogenic cell dea ...... ry therapy with TLR4 agonists.
@en
P2093
J P P Catani
M Freudenberg
P2860
P2888
P356
10.1038/CDD.2013.72
P50
P577
2013-06-28T00:00:00Z